Phillip Broadwith
As Business editor, my aim is to highlight to readers the exciting and innovative chemistry going on in the commercial sector, as well as keeping you abreast of trends and developments in the world of chemistry businesses.
From the point I left school, my aim was to join the pharmaceutical industry. A gap year and summer placements in company labs, and a PhD in organic synthesis followed.
But halfway through my PhD I entered a writing competition run by the Daily Telegraph. I managed to win – somewhat to my own surprise. That changed my perspective and made me think that I should consider writing more seriously as a career. I joined the Royal Society of Chemistry just before submitting my thesis, and luckily a position with Chemistry World came up a few months later. I sometimes miss the thrills (less so the spills) of lab work, but interacting with world-leading scientists and industrialists, as well as learning new things on a daily basis more than makes up for it.
Contact info
- Email:
- broadwithp@rsc.org
OpinionFossil industries promise net emissions reductions
Can the oil industry really curb its carbon output fast enough to impact climate targets?
- Opinion
Startup EQRx claims it can revolutionise drug discovery
If it can deliver reasonable drugs at knock-down prices, will providers be convinced?
- Business
Deadly explosion at ethylene oxide plant in Spain
Two employees killed and seven others injured at Iqoxe plant in Tarragona
- Business
Two dead at US industrial tank cleaning site
Workers overcome by fumes in enclosed tanker truck
- Review
Antimony, Gold, and Jupiter’s Wolf: How the Elements Were Named
Accessible to chemists and non-chemists alike, this book traces the evolution of our understanding of the nature of matter itself
- Podcast
Book Club – Antimony, Gold, and Jupiter’s Wolf by Peter Wothers
We talk about chemist Peter Wothers’ first popular science book that uncovers the surprising origins of the elements’ names
- Opinion
When should employees share profits from inventions?
Glucose monitor inventor wins £2m payout from Unilever after claiming his work provided ’outstanding benefit’
- Opinion
Is bankruptcy best for Purdue?
Many would prefer to see the Sackler family held personally liable, and the company wound down
- Opinion
Will Novartis's data manipulation damage relations with regulators?
Trust between the two has been compromised
- Opinion
Are new drugs better than existing ones?
Should companies be made to change the way they run clinical trials?
- Opinion
Get with the quantum program
Now is the time for industry to engage with the emerging world of quantum computers
- Opinion
Is Bayer regretting its Monsanto takeover?
Large damages in Roundup litigation have got investors questioning the move
- Business
At least six dead in explosions in US and Russia
Blasts at silicones and fertiliser plants each leave three confirmed dead
- Opinion
Show me the data
Making industrial safety research more transparent benefits both companies and consumers
- Business
Deadly explosion at US chemical plant
Isobutylene tank explosion kills one and hospitalises two at KMCO plant in Crosby
- Business
What might Brexit mean for industry?
Questions hang over regulation, trade, talent and investment
- Opinion
Divergent reality
If the UK leaves the EU without a deal, the two will inevitably drift further apart
